Trial Profile
Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2019
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms ARILAI
- Sponsors Abdi Ibrahim Otsuka Pharmaceutical
- 05 Mar 2019 Status changed from not yet recruiting to completed.
- 10 Mar 2016 New trial record